nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—HIF1A—kidney cancer	0.247	0.523	CbGaD
Carvedilol—VEGFA—kidney cancer	0.0995	0.211	CbGaD
Carvedilol—PTGS1—kidney cancer	0.0525	0.111	CbGaD
Carvedilol—CYP1A1—kidney cancer	0.048	0.102	CbGaD
Carvedilol—ABCB1—kidney cancer	0.0255	0.054	CbGaD
Carvedilol—XDH—Doxorubicin—kidney cancer	0.0245	0.1	CbGbCtD
Carvedilol—ABCB1—Temsirolimus—kidney cancer	0.0151	0.0618	CbGbCtD
Carvedilol—KCNH2—Sunitinib—kidney cancer	0.0149	0.0611	CbGbCtD
Carvedilol—CYP1A1—Erlotinib—kidney cancer	0.0145	0.0593	CbGbCtD
Carvedilol—CYP2D6—Temsirolimus—kidney cancer	0.0142	0.0582	CbGbCtD
Carvedilol—CYP3A4—Everolimus—kidney cancer	0.0134	0.0548	CbGbCtD
Carvedilol—CYP1A2—Pazopanib—kidney cancer	0.00905	0.0371	CbGbCtD
Carvedilol—CYP3A4—Temsirolimus—kidney cancer	0.00903	0.037	CbGbCtD
Carvedilol—CYP2C9—Capecitabine—kidney cancer	0.00851	0.0349	CbGbCtD
Carvedilol—ABCB1—Pazopanib—kidney cancer	0.00792	0.0325	CbGbCtD
Carvedilol—CYP2D6—Pazopanib—kidney cancer	0.00746	0.0306	CbGbCtD
Carvedilol—ABCB1—Dactinomycin—kidney cancer	0.00724	0.0297	CbGbCtD
Carvedilol—CYP1A2—Erlotinib—kidney cancer	0.00646	0.0265	CbGbCtD
Carvedilol—ABCB1—Gemcitabine—kidney cancer	0.00572	0.0235	CbGbCtD
Carvedilol—ABCB1—Erlotinib—kidney cancer	0.00565	0.0232	CbGbCtD
Carvedilol—CYP2C9—Paclitaxel—kidney cancer	0.00533	0.0218	CbGbCtD
Carvedilol—CYP2D6—Erlotinib—kidney cancer	0.00532	0.0218	CbGbCtD
Carvedilol—CYP1A2—Sorafenib—kidney cancer	0.00525	0.0215	CbGbCtD
Carvedilol—ABCB1—Paclitaxel—kidney cancer	0.00517	0.0212	CbGbCtD
Carvedilol—CYP3A4—Pazopanib—kidney cancer	0.00474	0.0194	CbGbCtD
Carvedilol—CYP2C9—Sorafenib—kidney cancer	0.00473	0.0194	CbGbCtD
Carvedilol—ABCB1—Sorafenib—kidney cancer	0.00459	0.0188	CbGbCtD
Carvedilol—ABCB1—Vinblastine—kidney cancer	0.00454	0.0186	CbGbCtD
Carvedilol—ABCB1—Vincristine—kidney cancer	0.00446	0.0183	CbGbCtD
Carvedilol—CYP2D6—Sorafenib—kidney cancer	0.00433	0.0177	CbGbCtD
Carvedilol—CYP2D6—Vinblastine—kidney cancer	0.00427	0.0175	CbGbCtD
Carvedilol—ABCB1—Sunitinib—kidney cancer	0.00372	0.0153	CbGbCtD
Carvedilol—CYP3A4—Erlotinib—kidney cancer	0.00338	0.0139	CbGbCtD
Carvedilol—CYP3A4—Paclitaxel—kidney cancer	0.0031	0.0127	CbGbCtD
Carvedilol—ABCB1—Doxorubicin—kidney cancer	0.00279	0.0114	CbGbCtD
Carvedilol—CYP3A4—Sorafenib—kidney cancer	0.00275	0.0113	CbGbCtD
Carvedilol—CYP3A4—Vinblastine—kidney cancer	0.00272	0.0111	CbGbCtD
Carvedilol—CYP3A4—Vincristine—kidney cancer	0.00267	0.011	CbGbCtD
Carvedilol—CYP2D6—Doxorubicin—kidney cancer	0.00263	0.0108	CbGbCtD
Carvedilol—CYP3A4—Sunitinib—kidney cancer	0.00223	0.00914	CbGbCtD
Carvedilol—NPPB—cardiac atrium—kidney cancer	0.00172	0.0366	CbGeAlD
Carvedilol—CYP3A4—Doxorubicin—kidney cancer	0.00167	0.00685	CbGbCtD
Carvedilol—SELE—nephron tubule—kidney cancer	0.00143	0.0304	CbGeAlD
Carvedilol—VCAM1—nephron tubule—kidney cancer	0.00131	0.028	CbGeAlD
Carvedilol—SELE—renal system—kidney cancer	0.0013	0.0276	CbGeAlD
Carvedilol—HIF1A—nephron tubule—kidney cancer	0.00126	0.0269	CbGeAlD
Carvedilol—GJA1—nephron tubule—kidney cancer	0.00122	0.0261	CbGeAlD
Carvedilol—SELE—cortex of kidney—kidney cancer	0.00122	0.026	CbGeAlD
Carvedilol—VCAM1—renal system—kidney cancer	0.00119	0.0254	CbGeAlD
Carvedilol—VCAM1—kidney—kidney cancer	0.00115	0.0246	CbGeAlD
Carvedilol—HIF1A—renal system—kidney cancer	0.00115	0.0245	CbGeAlD
Carvedilol—VCAM1—cortex of kidney—kidney cancer	0.00112	0.0239	CbGeAlD
Carvedilol—CYP1A2—urine—kidney cancer	0.00111	0.0238	CbGeAlD
Carvedilol—GJA1—renal system—kidney cancer	0.00111	0.0237	CbGeAlD
Carvedilol—HIF1A—kidney—kidney cancer	0.00111	0.0236	CbGeAlD
Carvedilol—HIF1A—cortex of kidney—kidney cancer	0.00108	0.023	CbGeAlD
Carvedilol—GJA1—kidney—kidney cancer	0.00108	0.0229	CbGeAlD
Carvedilol—VCAM1—cardiac atrium—kidney cancer	0.00107	0.0228	CbGeAlD
Carvedilol—CYP2C9—urine—kidney cancer	0.00106	0.0225	CbGeAlD
Carvedilol—GJA1—cortex of kidney—kidney cancer	0.00105	0.0223	CbGeAlD
Carvedilol—HIF1A—gonad—kidney cancer	0.00103	0.0219	CbGeAlD
Carvedilol—HIF1A—cardiac atrium—kidney cancer	0.00103	0.0219	CbGeAlD
Carvedilol—CYP2E1—urine—kidney cancer	0.001	0.0214	CbGeAlD
Carvedilol—GJA1—gonad—kidney cancer	0.000998	0.0213	CbGeAlD
Carvedilol—GJA1—cardiac atrium—kidney cancer	0.000996	0.0212	CbGeAlD
Carvedilol—NDUFC2—renal system—kidney cancer	0.000968	0.0206	CbGeAlD
Carvedilol—VEGFA—nephron tubule—kidney cancer	0.000966	0.0206	CbGeAlD
Carvedilol—NDUFC2—kidney—kidney cancer	0.000936	0.02	CbGeAlD
Carvedilol—NDUFC2—cortex of kidney—kidney cancer	0.000912	0.0194	CbGeAlD
Carvedilol—GJA1—Vinorelbine—Vincristine—kidney cancer	0.000907	0.5	CbGdCrCtD
Carvedilol—GJA1—Vinorelbine—Vinblastine—kidney cancer	0.000907	0.5	CbGdCrCtD
Carvedilol—NDUFC2—gonad—kidney cancer	0.000868	0.0185	CbGeAlD
Carvedilol—NDUFC2—cardiac atrium—kidney cancer	0.000867	0.0185	CbGeAlD
Carvedilol—VEGFA—cortex of kidney—kidney cancer	0.000827	0.0176	CbGeAlD
Carvedilol—CYP3A4—urine—kidney cancer	0.000806	0.0172	CbGeAlD
Carvedilol—CYP2D6—urine—kidney cancer	0.000794	0.0169	CbGeAlD
Carvedilol—VEGFA—cardiac atrium—kidney cancer	0.000787	0.0168	CbGeAlD
Carvedilol—XDH—renal system—kidney cancer	0.000782	0.0167	CbGeAlD
Carvedilol—XDH—kidney—kidney cancer	0.000756	0.0161	CbGeAlD
Carvedilol—ADRA1B—renal system—kidney cancer	0.000587	0.0125	CbGeAlD
Carvedilol—ADRA1B—kidney—kidney cancer	0.000567	0.0121	CbGeAlD
Carvedilol—ADRB1—cardiac atrium—kidney cancer	0.000373	0.00796	CbGeAlD
Carvedilol—ADRA2C—nephron tubule—kidney cancer	0.000346	0.00737	CbGeAlD
Carvedilol—ADRA1A—renal system—kidney cancer	0.00033	0.00703	CbGeAlD
Carvedilol—KCNH2—renal system—kidney cancer	0.000318	0.00679	CbGeAlD
Carvedilol—ADRA2C—renal system—kidney cancer	0.000314	0.0067	CbGeAlD
Carvedilol—ADRA2C—kidney—kidney cancer	0.000304	0.00647	CbGeAlD
Carvedilol—ADRA2C—cortex of kidney—kidney cancer	0.000296	0.00631	CbGeAlD
Carvedilol—KCNH2—cardiac atrium—kidney cancer	0.000285	0.00608	CbGeAlD
Carvedilol—ADRA2C—cardiac atrium—kidney cancer	0.000281	0.006	CbGeAlD
Carvedilol—CYP1A2—renal system—kidney cancer	0.000273	0.00581	CbGeAlD
Carvedilol—CYP2E1—nephron tubule—kidney cancer	0.00027	0.00575	CbGeAlD
Carvedilol—CYP1A1—renal system—kidney cancer	0.000269	0.00573	CbGeAlD
Carvedilol—CYP1A1—kidney—kidney cancer	0.00026	0.00554	CbGeAlD
Carvedilol—CYP2E1—renal system—kidney cancer	0.000245	0.00523	CbGeAlD
Carvedilol—CYP1A1—cardiac atrium—kidney cancer	0.000241	0.00513	CbGeAlD
Carvedilol—CYP2E1—kidney—kidney cancer	0.000237	0.00505	CbGeAlD
Carvedilol—PTGS1—renal system—kidney cancer	0.000236	0.00504	CbGeAlD
Carvedilol—ADRA2A—cortex of kidney—kidney cancer	0.000236	0.00503	CbGeAlD
Carvedilol—CYP2E1—cortex of kidney—kidney cancer	0.000231	0.00492	CbGeAlD
Carvedilol—PTGS1—kidney—kidney cancer	0.000228	0.00487	CbGeAlD
Carvedilol—ADRA2A—gonad—kidney cancer	0.000225	0.00479	CbGeAlD
Carvedilol—ADRA2A—cardiac atrium—kidney cancer	0.000224	0.00479	CbGeAlD
Carvedilol—PTGS1—cardiac atrium—kidney cancer	0.000212	0.00451	CbGeAlD
Carvedilol—CYP3A4—renal system—kidney cancer	0.000197	0.00421	CbGeAlD
Carvedilol—CYP2D6—renal system—kidney cancer	0.000194	0.00414	CbGeAlD
Carvedilol—CYP3A4—kidney—kidney cancer	0.000191	0.00407	CbGeAlD
Carvedilol—CYP2D6—kidney—kidney cancer	0.000188	0.004	CbGeAlD
Carvedilol—ABCB1—nephron tubule—kidney cancer	0.000154	0.00328	CbGeAlD
Carvedilol—ABCB1—renal system—kidney cancer	0.00014	0.00298	CbGeAlD
Carvedilol—ABCB1—kidney—kidney cancer	0.000135	0.00288	CbGeAlD
Carvedilol—ABCB1—cortex of kidney—kidney cancer	0.000131	0.0028	CbGeAlD
Carvedilol—ABCB1—gonad—kidney cancer	0.000125	0.00267	CbGeAlD
Carvedilol—Myalgia—Paclitaxel—kidney cancer	5.05e-05	0.000402	CcSEcCtD
Carvedilol—Chest pain—Paclitaxel—kidney cancer	5.05e-05	0.000402	CcSEcCtD
Carvedilol—Mediastinal disorder—Capecitabine—kidney cancer	5.04e-05	0.000401	CcSEcCtD
Carvedilol—Decreased appetite—Gemcitabine—kidney cancer	5.03e-05	0.0004	CcSEcCtD
Carvedilol—Hypersensitivity—Dactinomycin—kidney cancer	5.03e-05	0.0004	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	5.02e-05	0.000399	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Gemcitabine—kidney cancer	5e-05	0.000397	CcSEcCtD
Carvedilol—Discomfort—Paclitaxel—kidney cancer	4.99e-05	0.000397	CcSEcCtD
Carvedilol—Fatigue—Gemcitabine—kidney cancer	4.99e-05	0.000397	CcSEcCtD
Carvedilol—Gastrointestinal pain—Vincristine—kidney cancer	4.99e-05	0.000397	CcSEcCtD
Carvedilol—Cardiac arrest—Doxorubicin—kidney cancer	4.96e-05	0.000394	CcSEcCtD
Carvedilol—Dizziness—Sorafenib—kidney cancer	4.96e-05	0.000394	CcSEcCtD
Carvedilol—Constipation—Gemcitabine—kidney cancer	4.95e-05	0.000394	CcSEcCtD
Carvedilol—Pain—Gemcitabine—kidney cancer	4.95e-05	0.000394	CcSEcCtD
Carvedilol—Nausea—Erlotinib—kidney cancer	4.95e-05	0.000394	CcSEcCtD
Carvedilol—Alopecia—Capecitabine—kidney cancer	4.95e-05	0.000393	CcSEcCtD
Carvedilol—Dry mouth—Paclitaxel—kidney cancer	4.94e-05	0.000393	CcSEcCtD
Carvedilol—Mood swings—Doxorubicin—kidney cancer	4.94e-05	0.000393	CcSEcCtD
Carvedilol—Diarrhoea—Sunitinib—kidney cancer	4.93e-05	0.000392	CcSEcCtD
Carvedilol—Asthenia—Dactinomycin—kidney cancer	4.9e-05	0.00039	CcSEcCtD
Carvedilol—Confusional state—Paclitaxel—kidney cancer	4.89e-05	0.000389	CcSEcCtD
Carvedilol—Blood creatinine increased—Doxorubicin—kidney cancer	4.88e-05	0.000389	CcSEcCtD
Carvedilol—Malnutrition—Capecitabine—kidney cancer	4.87e-05	0.000387	CcSEcCtD
Carvedilol—Dehydration—Doxorubicin—kidney cancer	4.85e-05	0.000386	CcSEcCtD
Carvedilol—Anaphylactic shock—Paclitaxel—kidney cancer	4.84e-05	0.000385	CcSEcCtD
Carvedilol—Oedema—Paclitaxel—kidney cancer	4.84e-05	0.000385	CcSEcCtD
Carvedilol—Abdominal pain—Vincristine—kidney cancer	4.82e-05	0.000384	CcSEcCtD
Carvedilol—Body temperature increased—Vincristine—kidney cancer	4.82e-05	0.000384	CcSEcCtD
Carvedilol—Infection—Paclitaxel—kidney cancer	4.81e-05	0.000383	CcSEcCtD
Carvedilol—Flatulence—Capecitabine—kidney cancer	4.8e-05	0.000382	CcSEcCtD
Carvedilol—Dizziness—Sunitinib—kidney cancer	4.77e-05	0.000379	CcSEcCtD
Carvedilol—Feeling abnormal—Gemcitabine—kidney cancer	4.77e-05	0.000379	CcSEcCtD
Carvedilol—Shock—Paclitaxel—kidney cancer	4.77e-05	0.000379	CcSEcCtD
Carvedilol—Vomiting—Sorafenib—kidney cancer	4.77e-05	0.000379	CcSEcCtD
Carvedilol—Orthostatic hypotension—Doxorubicin—kidney cancer	4.76e-05	0.000379	CcSEcCtD
Carvedilol—Hypokalaemia—Doxorubicin—kidney cancer	4.75e-05	0.000377	CcSEcCtD
Carvedilol—Thrombocytopenia—Paclitaxel—kidney cancer	4.74e-05	0.000377	CcSEcCtD
Carvedilol—Tachycardia—Paclitaxel—kidney cancer	4.73e-05	0.000376	CcSEcCtD
Carvedilol—Rash—Sorafenib—kidney cancer	4.73e-05	0.000376	CcSEcCtD
Carvedilol—Dermatitis—Sorafenib—kidney cancer	4.72e-05	0.000375	CcSEcCtD
Carvedilol—Back pain—Capecitabine—kidney cancer	4.71e-05	0.000375	CcSEcCtD
Carvedilol—Skin disorder—Paclitaxel—kidney cancer	4.71e-05	0.000374	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	4.7e-05	0.000373	CcSEcCtD
Carvedilol—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	4.7e-05	0.000373	CcSEcCtD
Carvedilol—Headache—Sorafenib—kidney cancer	4.7e-05	0.000373	CcSEcCtD
Carvedilol—Muscle spasms—Capecitabine—kidney cancer	4.68e-05	0.000373	CcSEcCtD
Carvedilol—Hyperhidrosis—Paclitaxel—kidney cancer	4.68e-05	0.000373	CcSEcCtD
Carvedilol—Diarrhoea—Dactinomycin—kidney cancer	4.67e-05	0.000372	CcSEcCtD
Carvedilol—Nasopharyngitis—Doxorubicin—kidney cancer	4.66e-05	0.000371	CcSEcCtD
Carvedilol—Anorexia—Paclitaxel—kidney cancer	4.62e-05	0.000367	CcSEcCtD
Carvedilol—Alanine aminotransferase increased—Doxorubicin—kidney cancer	4.6e-05	0.000366	CcSEcCtD
Carvedilol—Vision blurred—Capecitabine—kidney cancer	4.59e-05	0.000365	CcSEcCtD
Carvedilol—Vomiting—Sunitinib—kidney cancer	4.59e-05	0.000365	CcSEcCtD
Carvedilol—Body temperature increased—Gemcitabine—kidney cancer	4.57e-05	0.000364	CcSEcCtD
Carvedilol—Rash—Sunitinib—kidney cancer	4.55e-05	0.000362	CcSEcCtD
Carvedilol—Dermatitis—Sunitinib—kidney cancer	4.54e-05	0.000361	CcSEcCtD
Carvedilol—Hypotension—Paclitaxel—kidney cancer	4.53e-05	0.00036	CcSEcCtD
Carvedilol—Ill-defined disorder—Capecitabine—kidney cancer	4.52e-05	0.000359	CcSEcCtD
Carvedilol—Headache—Sunitinib—kidney cancer	4.52e-05	0.000359	CcSEcCtD
Carvedilol—Influenza—Doxorubicin—kidney cancer	4.51e-05	0.000358	CcSEcCtD
Carvedilol—Anaemia—Capecitabine—kidney cancer	4.5e-05	0.000358	CcSEcCtD
Carvedilol—Hypersensitivity—Vincristine—kidney cancer	4.49e-05	0.000357	CcSEcCtD
Carvedilol—Nausea—Sorafenib—kidney cancer	4.45e-05	0.000354	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Paclitaxel—kidney cancer	4.41e-05	0.000351	CcSEcCtD
Carvedilol—Malaise—Capecitabine—kidney cancer	4.39e-05	0.000349	CcSEcCtD
Carvedilol—Angina pectoris—Doxorubicin—kidney cancer	4.39e-05	0.000349	CcSEcCtD
Carvedilol—Insomnia—Paclitaxel—kidney cancer	4.38e-05	0.000349	CcSEcCtD
Carvedilol—Vertigo—Capecitabine—kidney cancer	4.38e-05	0.000348	CcSEcCtD
Carvedilol—Asthenia—Vincristine—kidney cancer	4.38e-05	0.000348	CcSEcCtD
Carvedilol—Syncope—Capecitabine—kidney cancer	4.37e-05	0.000347	CcSEcCtD
Carvedilol—Leukopenia—Capecitabine—kidney cancer	4.36e-05	0.000347	CcSEcCtD
Carvedilol—Paraesthesia—Paclitaxel—kidney cancer	4.35e-05	0.000346	CcSEcCtD
Carvedilol—Vomiting—Dactinomycin—kidney cancer	4.34e-05	0.000345	CcSEcCtD
Carvedilol—Bronchitis—Doxorubicin—kidney cancer	4.33e-05	0.000345	CcSEcCtD
Carvedilol—Dyspnoea—Paclitaxel—kidney cancer	4.32e-05	0.000344	CcSEcCtD
Carvedilol—Somnolence—Paclitaxel—kidney cancer	4.31e-05	0.000343	CcSEcCtD
Carvedilol—Palpitations—Capecitabine—kidney cancer	4.31e-05	0.000342	CcSEcCtD
Carvedilol—Rash—Dactinomycin—kidney cancer	4.3e-05	0.000342	CcSEcCtD
Carvedilol—Nausea—Sunitinib—kidney cancer	4.28e-05	0.000341	CcSEcCtD
Carvedilol—Loss of consciousness—Capecitabine—kidney cancer	4.28e-05	0.000341	CcSEcCtD
Carvedilol—Pancytopenia—Doxorubicin—kidney cancer	4.28e-05	0.00034	CcSEcCtD
Carvedilol—Dyspepsia—Paclitaxel—kidney cancer	4.26e-05	0.000339	CcSEcCtD
Carvedilol—Cough—Capecitabine—kidney cancer	4.25e-05	0.000338	CcSEcCtD
Carvedilol—Decreased appetite—Paclitaxel—kidney cancer	4.21e-05	0.000335	CcSEcCtD
Carvedilol—Hypertension—Capecitabine—kidney cancer	4.21e-05	0.000335	CcSEcCtD
Carvedilol—Upper respiratory tract infection—Doxorubicin—kidney cancer	4.19e-05	0.000333	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Paclitaxel—kidney cancer	4.18e-05	0.000333	CcSEcCtD
Carvedilol—Fatigue—Paclitaxel—kidney cancer	4.18e-05	0.000332	CcSEcCtD
Carvedilol—Diarrhoea—Vincristine—kidney cancer	4.17e-05	0.000332	CcSEcCtD
Carvedilol—Pollakiuria—Doxorubicin—kidney cancer	4.16e-05	0.000331	CcSEcCtD
Carvedilol—Asthenia—Gemcitabine—kidney cancer	4.15e-05	0.00033	CcSEcCtD
Carvedilol—Arthralgia—Capecitabine—kidney cancer	4.15e-05	0.00033	CcSEcCtD
Carvedilol—Myalgia—Capecitabine—kidney cancer	4.15e-05	0.00033	CcSEcCtD
Carvedilol—Chest pain—Capecitabine—kidney cancer	4.15e-05	0.00033	CcSEcCtD
Carvedilol—Constipation—Paclitaxel—kidney cancer	4.14e-05	0.00033	CcSEcCtD
Carvedilol—Pain—Paclitaxel—kidney cancer	4.14e-05	0.00033	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	4.12e-05	0.000328	CcSEcCtD
Carvedilol—Photosensitivity reaction—Doxorubicin—kidney cancer	4.11e-05	0.000327	CcSEcCtD
Carvedilol—Weight increased—Doxorubicin—kidney cancer	4.1e-05	0.000326	CcSEcCtD
Carvedilol—Discomfort—Capecitabine—kidney cancer	4.1e-05	0.000326	CcSEcCtD
Carvedilol—Pruritus—Gemcitabine—kidney cancer	4.09e-05	0.000326	CcSEcCtD
Carvedilol—Weight decreased—Doxorubicin—kidney cancer	4.08e-05	0.000324	CcSEcCtD
Carvedilol—Hyperglycaemia—Doxorubicin—kidney cancer	4.07e-05	0.000323	CcSEcCtD
Carvedilol—Dry mouth—Capecitabine—kidney cancer	4.06e-05	0.000323	CcSEcCtD
Carvedilol—Nausea—Dactinomycin—kidney cancer	4.06e-05	0.000323	CcSEcCtD
Carvedilol—Pneumonia—Doxorubicin—kidney cancer	4.04e-05	0.000321	CcSEcCtD
Carvedilol—Dizziness—Vincristine—kidney cancer	4.03e-05	0.000321	CcSEcCtD
Carvedilol—Confusional state—Capecitabine—kidney cancer	4.01e-05	0.000319	CcSEcCtD
Carvedilol—Feeling abnormal—Paclitaxel—kidney cancer	3.99e-05	0.000318	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	3.98e-05	0.000317	CcSEcCtD
Carvedilol—Oedema—Capecitabine—kidney cancer	3.98e-05	0.000316	CcSEcCtD
Carvedilol—Gastrointestinal pain—Paclitaxel—kidney cancer	3.96e-05	0.000315	CcSEcCtD
Carvedilol—Diarrhoea—Gemcitabine—kidney cancer	3.96e-05	0.000315	CcSEcCtD
Carvedilol—Renal failure—Doxorubicin—kidney cancer	3.95e-05	0.000314	CcSEcCtD
Carvedilol—Infection—Capecitabine—kidney cancer	3.95e-05	0.000314	CcSEcCtD
Carvedilol—Shock—Capecitabine—kidney cancer	3.91e-05	0.000311	CcSEcCtD
Carvedilol—Urinary tract infection—Doxorubicin—kidney cancer	3.91e-05	0.000311	CcSEcCtD
Carvedilol—Thrombocytopenia—Capecitabine—kidney cancer	3.89e-05	0.00031	CcSEcCtD
Carvedilol—Tachycardia—Capecitabine—kidney cancer	3.88e-05	0.000309	CcSEcCtD
Carvedilol—Vomiting—Vincristine—kidney cancer	3.88e-05	0.000308	CcSEcCtD
Carvedilol—Skin disorder—Capecitabine—kidney cancer	3.86e-05	0.000307	CcSEcCtD
Carvedilol—Urticaria—Paclitaxel—kidney cancer	3.85e-05	0.000306	CcSEcCtD
Carvedilol—Rash—Vincristine—kidney cancer	3.85e-05	0.000306	CcSEcCtD
Carvedilol—Hyperhidrosis—Capecitabine—kidney cancer	3.84e-05	0.000306	CcSEcCtD
Carvedilol—Dermatitis—Vincristine—kidney cancer	3.84e-05	0.000306	CcSEcCtD
Carvedilol—Haematuria—Doxorubicin—kidney cancer	3.83e-05	0.000305	CcSEcCtD
Carvedilol—Body temperature increased—Paclitaxel—kidney cancer	3.83e-05	0.000305	CcSEcCtD
Carvedilol—Abdominal pain—Paclitaxel—kidney cancer	3.83e-05	0.000305	CcSEcCtD
Carvedilol—Headache—Vincristine—kidney cancer	3.82e-05	0.000304	CcSEcCtD
Carvedilol—Anorexia—Capecitabine—kidney cancer	3.79e-05	0.000301	CcSEcCtD
Carvedilol—Sinusitis—Doxorubicin—kidney cancer	3.77e-05	0.0003	CcSEcCtD
Carvedilol—Hypotension—Capecitabine—kidney cancer	3.72e-05	0.000295	CcSEcCtD
Carvedilol—Vomiting—Gemcitabine—kidney cancer	3.68e-05	0.000293	CcSEcCtD
Carvedilol—Bradycardia—Doxorubicin—kidney cancer	3.67e-05	0.000292	CcSEcCtD
Carvedilol—Rash—Gemcitabine—kidney cancer	3.65e-05	0.00029	CcSEcCtD
Carvedilol—Dermatitis—Gemcitabine—kidney cancer	3.65e-05	0.00029	CcSEcCtD
Carvedilol—Haemoglobin—Doxorubicin—kidney cancer	3.63e-05	0.000288	CcSEcCtD
Carvedilol—Headache—Gemcitabine—kidney cancer	3.63e-05	0.000288	CcSEcCtD
Carvedilol—Nausea—Vincristine—kidney cancer	3.62e-05	0.000288	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Capecitabine—kidney cancer	3.62e-05	0.000288	CcSEcCtD
Carvedilol—Rhinitis—Doxorubicin—kidney cancer	3.62e-05	0.000288	CcSEcCtD
Carvedilol—Haemorrhage—Doxorubicin—kidney cancer	3.61e-05	0.000287	CcSEcCtD
Carvedilol—Insomnia—Capecitabine—kidney cancer	3.6e-05	0.000286	CcSEcCtD
Carvedilol—Hypoaesthesia—Doxorubicin—kidney cancer	3.59e-05	0.000285	CcSEcCtD
Carvedilol—Pharyngitis—Doxorubicin—kidney cancer	3.58e-05	0.000285	CcSEcCtD
Carvedilol—Paraesthesia—Capecitabine—kidney cancer	3.57e-05	0.000284	CcSEcCtD
Carvedilol—Hypersensitivity—Paclitaxel—kidney cancer	3.57e-05	0.000284	CcSEcCtD
Carvedilol—Urinary tract disorder—Doxorubicin—kidney cancer	3.56e-05	0.000283	CcSEcCtD
Carvedilol—Oedema peripheral—Doxorubicin—kidney cancer	3.55e-05	0.000283	CcSEcCtD
Carvedilol—Dyspnoea—Capecitabine—kidney cancer	3.54e-05	0.000282	CcSEcCtD
Carvedilol—Urethral disorder—Doxorubicin—kidney cancer	3.54e-05	0.000281	CcSEcCtD
Carvedilol—Dyspepsia—Capecitabine—kidney cancer	3.5e-05	0.000278	CcSEcCtD
Carvedilol—Visual impairment—Doxorubicin—kidney cancer	3.48e-05	0.000276	CcSEcCtD
Carvedilol—Asthenia—Paclitaxel—kidney cancer	3.48e-05	0.000276	CcSEcCtD
Carvedilol—Decreased appetite—Capecitabine—kidney cancer	3.46e-05	0.000275	CcSEcCtD
Carvedilol—Nausea—Gemcitabine—kidney cancer	3.44e-05	0.000273	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Capecitabine—kidney cancer	3.43e-05	0.000273	CcSEcCtD
Carvedilol—Fatigue—Capecitabine—kidney cancer	3.43e-05	0.000273	CcSEcCtD
Carvedilol—Pruritus—Paclitaxel—kidney cancer	3.43e-05	0.000273	CcSEcCtD
Carvedilol—Erythema multiforme—Doxorubicin—kidney cancer	3.41e-05	0.000271	CcSEcCtD
Carvedilol—Constipation—Capecitabine—kidney cancer	3.4e-05	0.00027	CcSEcCtD
Carvedilol—Pain—Capecitabine—kidney cancer	3.4e-05	0.00027	CcSEcCtD
Carvedilol—Tinnitus—Doxorubicin—kidney cancer	3.36e-05	0.000267	CcSEcCtD
Carvedilol—Diarrhoea—Paclitaxel—kidney cancer	3.31e-05	0.000264	CcSEcCtD
Carvedilol—Feeling abnormal—Capecitabine—kidney cancer	3.28e-05	0.000261	CcSEcCtD
Carvedilol—Angiopathy—Doxorubicin—kidney cancer	3.27e-05	0.00026	CcSEcCtD
Carvedilol—Immune system disorder—Doxorubicin—kidney cancer	3.26e-05	0.000259	CcSEcCtD
Carvedilol—Gastrointestinal pain—Capecitabine—kidney cancer	3.25e-05	0.000259	CcSEcCtD
Carvedilol—Mediastinal disorder—Doxorubicin—kidney cancer	3.25e-05	0.000259	CcSEcCtD
Carvedilol—Dizziness—Paclitaxel—kidney cancer	3.2e-05	0.000255	CcSEcCtD
Carvedilol—Alopecia—Doxorubicin—kidney cancer	3.19e-05	0.000254	CcSEcCtD
Carvedilol—Urticaria—Capecitabine—kidney cancer	3.16e-05	0.000251	CcSEcCtD
Carvedilol—Body temperature increased—Capecitabine—kidney cancer	3.14e-05	0.00025	CcSEcCtD
Carvedilol—Abdominal pain—Capecitabine—kidney cancer	3.14e-05	0.00025	CcSEcCtD
Carvedilol—Malnutrition—Doxorubicin—kidney cancer	3.14e-05	0.00025	CcSEcCtD
Carvedilol—Flatulence—Doxorubicin—kidney cancer	3.09e-05	0.000246	CcSEcCtD
Carvedilol—Tension—Doxorubicin—kidney cancer	3.08e-05	0.000245	CcSEcCtD
Carvedilol—Vomiting—Paclitaxel—kidney cancer	3.08e-05	0.000245	CcSEcCtD
Carvedilol—Rash—Paclitaxel—kidney cancer	3.05e-05	0.000243	CcSEcCtD
Carvedilol—Dermatitis—Paclitaxel—kidney cancer	3.05e-05	0.000243	CcSEcCtD
Carvedilol—Nervousness—Doxorubicin—kidney cancer	3.05e-05	0.000243	CcSEcCtD
Carvedilol—Back pain—Doxorubicin—kidney cancer	3.04e-05	0.000242	CcSEcCtD
Carvedilol—Headache—Paclitaxel—kidney cancer	3.04e-05	0.000241	CcSEcCtD
Carvedilol—Muscle spasms—Doxorubicin—kidney cancer	3.02e-05	0.00024	CcSEcCtD
Carvedilol—Vision blurred—Doxorubicin—kidney cancer	2.96e-05	0.000235	CcSEcCtD
Carvedilol—Hypersensitivity—Capecitabine—kidney cancer	2.93e-05	0.000233	CcSEcCtD
Carvedilol—Ill-defined disorder—Doxorubicin—kidney cancer	2.91e-05	0.000232	CcSEcCtD
Carvedilol—Anaemia—Doxorubicin—kidney cancer	2.9e-05	0.000231	CcSEcCtD
Carvedilol—Nausea—Paclitaxel—kidney cancer	2.88e-05	0.000229	CcSEcCtD
Carvedilol—Asthenia—Capecitabine—kidney cancer	2.85e-05	0.000227	CcSEcCtD
Carvedilol—Malaise—Doxorubicin—kidney cancer	2.83e-05	0.000225	CcSEcCtD
Carvedilol—Vertigo—Doxorubicin—kidney cancer	2.82e-05	0.000224	CcSEcCtD
Carvedilol—Syncope—Doxorubicin—kidney cancer	2.82e-05	0.000224	CcSEcCtD
Carvedilol—Pruritus—Capecitabine—kidney cancer	2.81e-05	0.000224	CcSEcCtD
Carvedilol—Leukopenia—Doxorubicin—kidney cancer	2.81e-05	0.000224	CcSEcCtD
Carvedilol—Palpitations—Doxorubicin—kidney cancer	2.78e-05	0.000221	CcSEcCtD
Carvedilol—Loss of consciousness—Doxorubicin—kidney cancer	2.76e-05	0.00022	CcSEcCtD
Carvedilol—Cough—Doxorubicin—kidney cancer	2.74e-05	0.000218	CcSEcCtD
Carvedilol—Convulsion—Doxorubicin—kidney cancer	2.72e-05	0.000216	CcSEcCtD
Carvedilol—Diarrhoea—Capecitabine—kidney cancer	2.72e-05	0.000216	CcSEcCtD
Carvedilol—Hypertension—Doxorubicin—kidney cancer	2.71e-05	0.000216	CcSEcCtD
Carvedilol—Chest pain—Doxorubicin—kidney cancer	2.67e-05	0.000213	CcSEcCtD
Carvedilol—Myalgia—Doxorubicin—kidney cancer	2.67e-05	0.000213	CcSEcCtD
Carvedilol—Arthralgia—Doxorubicin—kidney cancer	2.67e-05	0.000213	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	2.66e-05	0.000211	CcSEcCtD
Carvedilol—Discomfort—Doxorubicin—kidney cancer	2.64e-05	0.00021	CcSEcCtD
Carvedilol—Dizziness—Capecitabine—kidney cancer	2.63e-05	0.000209	CcSEcCtD
Carvedilol—Dry mouth—Doxorubicin—kidney cancer	2.61e-05	0.000208	CcSEcCtD
Carvedilol—Confusional state—Doxorubicin—kidney cancer	2.58e-05	0.000206	CcSEcCtD
Carvedilol—Oedema—Doxorubicin—kidney cancer	2.56e-05	0.000204	CcSEcCtD
Carvedilol—Anaphylactic shock—Doxorubicin—kidney cancer	2.56e-05	0.000204	CcSEcCtD
Carvedilol—Infection—Doxorubicin—kidney cancer	2.55e-05	0.000202	CcSEcCtD
Carvedilol—Vomiting—Capecitabine—kidney cancer	2.53e-05	0.000201	CcSEcCtD
Carvedilol—Shock—Doxorubicin—kidney cancer	2.52e-05	0.000201	CcSEcCtD
Carvedilol—Thrombocytopenia—Doxorubicin—kidney cancer	2.51e-05	0.0002	CcSEcCtD
Carvedilol—Rash—Capecitabine—kidney cancer	2.51e-05	0.000199	CcSEcCtD
Carvedilol—Dermatitis—Capecitabine—kidney cancer	2.5e-05	0.000199	CcSEcCtD
Carvedilol—Tachycardia—Doxorubicin—kidney cancer	2.5e-05	0.000199	CcSEcCtD
Carvedilol—Headache—Capecitabine—kidney cancer	2.49e-05	0.000198	CcSEcCtD
Carvedilol—Skin disorder—Doxorubicin—kidney cancer	2.49e-05	0.000198	CcSEcCtD
Carvedilol—Hyperhidrosis—Doxorubicin—kidney cancer	2.48e-05	0.000197	CcSEcCtD
Carvedilol—Anorexia—Doxorubicin—kidney cancer	2.44e-05	0.000194	CcSEcCtD
Carvedilol—Hypotension—Doxorubicin—kidney cancer	2.39e-05	0.00019	CcSEcCtD
Carvedilol—Nausea—Capecitabine—kidney cancer	2.36e-05	0.000188	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Doxorubicin—kidney cancer	2.33e-05	0.000186	CcSEcCtD
Carvedilol—Insomnia—Doxorubicin—kidney cancer	2.32e-05	0.000184	CcSEcCtD
Carvedilol—Paraesthesia—Doxorubicin—kidney cancer	2.3e-05	0.000183	CcSEcCtD
Carvedilol—Dyspnoea—Doxorubicin—kidney cancer	2.28e-05	0.000182	CcSEcCtD
Carvedilol—Somnolence—Doxorubicin—kidney cancer	2.28e-05	0.000181	CcSEcCtD
Carvedilol—Dyspepsia—Doxorubicin—kidney cancer	2.26e-05	0.000179	CcSEcCtD
Carvedilol—Decreased appetite—Doxorubicin—kidney cancer	2.23e-05	0.000177	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Doxorubicin—kidney cancer	2.21e-05	0.000176	CcSEcCtD
Carvedilol—Fatigue—Doxorubicin—kidney cancer	2.21e-05	0.000176	CcSEcCtD
Carvedilol—Pain—Doxorubicin—kidney cancer	2.19e-05	0.000174	CcSEcCtD
Carvedilol—Constipation—Doxorubicin—kidney cancer	2.19e-05	0.000174	CcSEcCtD
Carvedilol—Feeling abnormal—Doxorubicin—kidney cancer	2.11e-05	0.000168	CcSEcCtD
Carvedilol—Gastrointestinal pain—Doxorubicin—kidney cancer	2.1e-05	0.000167	CcSEcCtD
Carvedilol—Urticaria—Doxorubicin—kidney cancer	2.04e-05	0.000162	CcSEcCtD
Carvedilol—Abdominal pain—Doxorubicin—kidney cancer	2.03e-05	0.000161	CcSEcCtD
Carvedilol—Body temperature increased—Doxorubicin—kidney cancer	2.03e-05	0.000161	CcSEcCtD
Carvedilol—Hypersensitivity—Doxorubicin—kidney cancer	1.89e-05	0.00015	CcSEcCtD
Carvedilol—Asthenia—Doxorubicin—kidney cancer	1.84e-05	0.000146	CcSEcCtD
Carvedilol—Pruritus—Doxorubicin—kidney cancer	1.81e-05	0.000144	CcSEcCtD
Carvedilol—Diarrhoea—Doxorubicin—kidney cancer	1.75e-05	0.000139	CcSEcCtD
Carvedilol—Dizziness—Doxorubicin—kidney cancer	1.69e-05	0.000135	CcSEcCtD
Carvedilol—Vomiting—Doxorubicin—kidney cancer	1.63e-05	0.00013	CcSEcCtD
Carvedilol—Rash—Doxorubicin—kidney cancer	1.62e-05	0.000129	CcSEcCtD
Carvedilol—Dermatitis—Doxorubicin—kidney cancer	1.61e-05	0.000128	CcSEcCtD
Carvedilol—Headache—Doxorubicin—kidney cancer	1.61e-05	0.000128	CcSEcCtD
Carvedilol—Nausea—Doxorubicin—kidney cancer	1.52e-05	0.000121	CcSEcCtD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.56e-06	1.43e-05	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—PIK3CA—kidney cancer	1.56e-06	1.43e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—RAF1—kidney cancer	1.56e-06	1.43e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—KRAS—kidney cancer	1.56e-06	1.43e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—GSTP1—kidney cancer	1.55e-06	1.43e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—RELA—kidney cancer	1.55e-06	1.42e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—KRAS—kidney cancer	1.55e-06	1.42e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—BRAF—kidney cancer	1.55e-06	1.42e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—POMC—kidney cancer	1.55e-06	1.42e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—KRAS—kidney cancer	1.55e-06	1.42e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HIF1A—kidney cancer	1.54e-06	1.42e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—KRAS—kidney cancer	1.54e-06	1.42e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—ERBB2—kidney cancer	1.54e-06	1.41e-05	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—PIK3CA—kidney cancer	1.54e-06	1.41e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TSC2—kidney cancer	1.54e-06	1.41e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—GSTP1—kidney cancer	1.54e-06	1.41e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.53e-06	1.4e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—MAPK1—kidney cancer	1.52e-06	1.4e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—KRAS—kidney cancer	1.52e-06	1.4e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MTOR—kidney cancer	1.52e-06	1.4e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PTGS2—kidney cancer	1.52e-06	1.4e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PTGS2—kidney cancer	1.52e-06	1.39e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—GSTM1—kidney cancer	1.51e-06	1.39e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—MAPK1—kidney cancer	1.5e-06	1.38e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.48e-06	1.36e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KDR—kidney cancer	1.48e-06	1.35e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ABCB1—kidney cancer	1.47e-06	1.35e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GSTT1—kidney cancer	1.46e-06	1.34e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ACHE—kidney cancer	1.46e-06	1.34e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KIT—kidney cancer	1.46e-06	1.34e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—APC—kidney cancer	1.46e-06	1.34e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—PIK3CA—kidney cancer	1.46e-06	1.34e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ABCB1—kidney cancer	1.46e-06	1.34e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—KRAS—kidney cancer	1.44e-06	1.32e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CYP1A1—kidney cancer	1.44e-06	1.32e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—PIK3CA—kidney cancer	1.43e-06	1.32e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—PIK3CA—kidney cancer	1.43e-06	1.31e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CDKN1B—kidney cancer	1.43e-06	1.31e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—GSTM1—kidney cancer	1.43e-06	1.31e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—PIK3CA—kidney cancer	1.42e-06	1.31e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—POMC—kidney cancer	1.42e-06	1.3e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—PIK3CA—kidney cancer	1.42e-06	1.3e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—RAF1—kidney cancer	1.42e-06	1.3e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—KRAS—kidney cancer	1.42e-06	1.3e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—PIK3CA—kidney cancer	1.42e-06	1.3e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—GSTM1—kidney cancer	1.41e-06	1.3e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—RELA—kidney cancer	1.41e-06	1.3e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—RAF1—kidney cancer	1.41e-06	1.29e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—ERBB2—kidney cancer	1.4e-06	1.29e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—MAPK3—kidney cancer	1.4e-06	1.29e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—RELA—kidney cancer	1.4e-06	1.29e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—PIK3CA—kidney cancer	1.4e-06	1.28e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL2—kidney cancer	1.4e-06	1.28e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—POMC—kidney cancer	1.39e-06	1.28e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—ERBB2—kidney cancer	1.39e-06	1.28e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—RAF1—kidney cancer	1.39e-06	1.27e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—SCARB1—kidney cancer	1.39e-06	1.27e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MTOR—kidney cancer	1.39e-06	1.27e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—RELA—kidney cancer	1.38e-06	1.27e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TP53—kidney cancer	1.38e-06	1.26e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—BRAF—kidney cancer	1.37e-06	1.26e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TP53—kidney cancer	1.37e-06	1.26e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—ERBB2—kidney cancer	1.37e-06	1.26e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MTOR—kidney cancer	1.37e-06	1.26e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTGS1—kidney cancer	1.37e-06	1.26e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CCND1—kidney cancer	1.36e-06	1.25e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—APC—kidney cancer	1.36e-06	1.25e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KIT—kidney cancer	1.36e-06	1.25e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—JUN—kidney cancer	1.36e-06	1.25e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MTOR—kidney cancer	1.36e-06	1.24e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CYP1A1—kidney cancer	1.35e-06	1.24e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CTNNB1—kidney cancer	1.35e-06	1.24e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PSMD7—kidney cancer	1.35e-06	1.24e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CYP1A1—kidney cancer	1.34e-06	1.23e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—POMC—kidney cancer	1.34e-06	1.23e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.33e-06	1.23e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—MAPK1—kidney cancer	1.33e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PTEN—kidney cancer	1.33e-06	1.22e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—PIK3CA—kidney cancer	1.32e-06	1.22e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PTEN—kidney cancer	1.32e-06	1.21e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—GSTP1—kidney cancer	1.32e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PTEN—kidney cancer	1.31e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—RAF1—kidney cancer	1.31e-06	1.21e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—RELA—kidney cancer	1.31e-06	1.2e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—PIK3CA—kidney cancer	1.3e-06	1.2e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—MAPK3—kidney cancer	1.3e-06	1.2e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CDKN1B—kidney cancer	1.3e-06	1.19e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—ERBB2—kidney cancer	1.3e-06	1.19e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—POMC—kidney cancer	1.29e-06	1.19e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—RAF1—kidney cancer	1.29e-06	1.19e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CDKN1B—kidney cancer	1.29e-06	1.18e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—RELA—kidney cancer	1.29e-06	1.18e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MTOR—kidney cancer	1.28e-06	1.18e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—ERBB2—kidney cancer	1.28e-06	1.17e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—BRAF—kidney cancer	1.28e-06	1.17e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—BCHE—kidney cancer	1.28e-06	1.17e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—PIK3CA—kidney cancer	1.27e-06	1.17e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL2—kidney cancer	1.27e-06	1.17e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CDKN1B—kidney cancer	1.27e-06	1.17e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MTOR—kidney cancer	1.26e-06	1.16e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL2—kidney cancer	1.26e-06	1.16e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—SLC5A5—kidney cancer	1.26e-06	1.16e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—KRAS—kidney cancer	1.26e-06	1.16e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ABCB1—kidney cancer	1.24e-06	1.14e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL2—kidney cancer	1.24e-06	1.14e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCND1—kidney cancer	1.24e-06	1.14e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—MAPK1—kidney cancer	1.24e-06	1.14e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—JUN—kidney cancer	1.24e-06	1.14e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTGS2—kidney cancer	1.23e-06	1.13e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCND1—kidney cancer	1.23e-06	1.13e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CTNNB1—kidney cancer	1.23e-06	1.13e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—JUN—kidney cancer	1.23e-06	1.13e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CTNNB1—kidney cancer	1.22e-06	1.12e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—SLC2A1—kidney cancer	1.22e-06	1.12e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCND1—kidney cancer	1.21e-06	1.11e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—JUN—kidney cancer	1.21e-06	1.11e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—GSTM1—kidney cancer	1.21e-06	1.11e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CDKN1B—kidney cancer	1.2e-06	1.11e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CTNNB1—kidney cancer	1.2e-06	1.1e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PTEN—kidney cancer	1.2e-06	1.1e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—VEGFA—kidney cancer	1.19e-06	1.09e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PTEN—kidney cancer	1.19e-06	1.09e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CDKN1B—kidney cancer	1.18e-06	1.09e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—PIK3CA—kidney cancer	1.18e-06	1.09e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL2—kidney cancer	1.18e-06	1.08e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PTEN—kidney cancer	1.17e-06	1.08e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—KRAS—kidney cancer	1.17e-06	1.07e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL2—kidney cancer	1.16e-06	1.06e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—PIK3CA—kidney cancer	1.16e-06	1.06e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—RAF1—kidney cancer	1.15e-06	1.05e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCND1—kidney cancer	1.15e-06	1.05e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CYP1A1—kidney cancer	1.15e-06	1.05e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—JUN—kidney cancer	1.15e-06	1.05e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—RELA—kidney cancer	1.14e-06	1.05e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CTNNB1—kidney cancer	1.14e-06	1.04e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ERBB2—kidney cancer	1.14e-06	1.04e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTGS2—kidney cancer	1.13e-06	1.04e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCND1—kidney cancer	1.13e-06	1.04e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—JUN—kidney cancer	1.13e-06	1.04e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MAPK3—kidney cancer	1.12e-06	1.03e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MTOR—kidney cancer	1.12e-06	1.03e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CTNNB1—kidney cancer	1.12e-06	1.03e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PTEN—kidney cancer	1.11e-06	1.02e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.1e-06	1.01e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MYC—kidney cancer	1.09e-06	1e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PTEN—kidney cancer	1.09e-06	1e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—VEGFA—kidney cancer	1.08e-06	9.93e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTEN—kidney cancer	1.08e-06	9.88e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—PIK3CA—kidney cancer	1.07e-06	9.87e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—VEGFA—kidney cancer	1.07e-06	9.84e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—POMC—kidney cancer	1.07e-06	9.83e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTGS2—kidney cancer	1.07e-06	9.81e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MAPK1—kidney cancer	1.07e-06	9.81e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—RAF1—kidney cancer	1.07e-06	9.8e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—RELA—kidney cancer	1.06e-06	9.75e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—VEGFA—kidney cancer	1.06e-06	9.71e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ERBB2—kidney cancer	1.06e-06	9.69e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CDKN1B—kidney cancer	1.05e-06	9.66e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MTOR—kidney cancer	1.04e-06	9.56e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL2—kidney cancer	1.03e-06	9.45e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MAPK3—kidney cancer	1.02e-06	9.39e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GSTP1—kidney cancer	1.01e-06	9.32e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MAPK3—kidney cancer	1.01e-06	9.31e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KRAS—kidney cancer	1.01e-06	9.26e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—POMC—kidney cancer	1.01e-06	9.26e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCND1—kidney cancer	1e-06	9.22e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—JUN—kidney cancer	1e-06	9.2e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—VEGFA—kidney cancer	1e-06	9.19e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MAPK3—kidney cancer	1e-06	9.19e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—POMC—kidney cancer	1e-06	9.18e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MYC—kidney cancer	9.95e-07	9.14e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CTNNB1—kidney cancer	9.94e-07	9.13e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTEN—kidney cancer	9.88e-07	9.08e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MYC—kidney cancer	9.86e-07	9.05e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—VEGFA—kidney cancer	9.85e-07	9.05e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CDKN1B—kidney cancer	9.77e-07	8.98e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MAPK1—kidney cancer	9.73e-07	8.94e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MYC—kidney cancer	9.73e-07	8.94e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PTEN—kidney cancer	9.69e-07	8.9e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MAPK1—kidney cancer	9.64e-07	8.86e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ABCB1—kidney cancer	9.61e-07	8.82e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL2—kidney cancer	9.56e-07	8.78e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MAPK1—kidney cancer	9.52e-07	8.74e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MAPK3—kidney cancer	9.47e-07	8.69e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	9.41e-07	8.64e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PIK3CA—kidney cancer	9.35e-07	8.58e-06	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PIK3CA—kidney cancer	9.33e-07	8.57e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GSTM1—kidney cancer	9.33e-07	8.56e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCND1—kidney cancer	9.32e-07	8.56e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTEN—kidney cancer	9.32e-07	8.56e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MAPK3—kidney cancer	9.32e-07	8.56e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—JUN—kidney cancer	9.3e-07	8.54e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PIK3CA—kidney cancer	9.27e-07	8.51e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CTNNB1—kidney cancer	9.23e-07	8.48e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MYC—kidney cancer	9.21e-07	8.46e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KRAS—kidney cancer	9.19e-07	8.44e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KRAS—kidney cancer	9.11e-07	8.36e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MYC—kidney cancer	9.06e-07	8.32e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MAPK1—kidney cancer	9.01e-07	8.27e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PTEN—kidney cancer	9e-07	8.26e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KRAS—kidney cancer	8.99e-07	8.26e-06	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—kidney cancer	8.97e-07	8.23e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MAPK1—kidney cancer	8.87e-07	8.14e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CYP1A1—kidney cancer	8.84e-07	8.12e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—VEGFA—kidney cancer	8.75e-07	8.03e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—POMC—kidney cancer	8.54e-07	7.84e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTGS2—kidney cancer	8.53e-07	7.84e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KRAS—kidney cancer	8.51e-07	7.81e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PIK3CA—kidney cancer	8.44e-07	7.76e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KRAS—kidney cancer	8.37e-07	7.69e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PIK3CA—kidney cancer	8.37e-07	7.68e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MAPK3—kidney cancer	8.28e-07	7.6e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PIK3CA—kidney cancer	8.26e-07	7.59e-06	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—kidney cancer	8.17e-07	7.5e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—VEGFA—kidney cancer	8.13e-07	7.46e-06	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—kidney cancer	8.1e-07	7.43e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MYC—kidney cancer	8.05e-07	7.39e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTGS2—kidney cancer	8.04e-07	7.39e-06	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—kidney cancer	7.99e-07	7.34e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTGS2—kidney cancer	7.97e-07	7.32e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MAPK1—kidney cancer	7.87e-07	7.23e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PIK3CA—kidney cancer	7.82e-07	7.18e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PIK3CA—kidney cancer	7.69e-07	7.06e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MAPK3—kidney cancer	7.69e-07	7.06e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PIK3CA—kidney cancer	7.59e-07	6.97e-06	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—kidney cancer	7.56e-07	6.94e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MYC—kidney cancer	7.48e-07	6.87e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTEN—kidney cancer	7.44e-07	6.83e-06	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—kidney cancer	7.44e-07	6.83e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KRAS—kidney cancer	7.44e-07	6.83e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MAPK1—kidney cancer	7.32e-07	6.72e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTEN—kidney cancer	7.01e-07	6.44e-06	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PIK3CA—kidney cancer	6.97e-07	6.4e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTEN—kidney cancer	6.95e-07	6.39e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KRAS—kidney cancer	6.91e-07	6.35e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PIK3CA—kidney cancer	6.83e-07	6.28e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTGS2—kidney cancer	6.81e-07	6.26e-06	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—kidney cancer	6.61e-07	6.07e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—POMC—kidney cancer	6.59e-07	6.05e-06	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PIK3CA—kidney cancer	6.57e-07	6.04e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PIK3CA—kidney cancer	6.35e-07	5.83e-06	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—kidney cancer	6.14e-07	5.64e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTEN—kidney cancer	5.94e-07	5.46e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTGS2—kidney cancer	5.26e-07	4.83e-06	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PIK3CA—kidney cancer	5.25e-07	4.82e-06	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PIK3CA—kidney cancer	4.95e-07	4.54e-06	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PIK3CA—kidney cancer	4.9e-07	4.5e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTEN—kidney cancer	4.59e-07	4.21e-06	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PIK3CA—kidney cancer	4.19e-07	3.85e-06	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PIK3CA—kidney cancer	3.23e-07	2.97e-06	CbGpPWpGaD
